Rein Therapeutics
RNTX
39 hedge funds and large institutions have $10.6M invested in Rein Therapeutics in 2025 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 2 closing their positions.
400% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 2
26% more funds holding
Funds holding: 31 → 39 (+8)
17% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 6
1.56% more ownership
Funds ownership: 26.21% → 27.77% (+1.6%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
19% less capital invested
Capital invested by funds: $13.1M → $10.6M (-$2.42M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$612K |
| 2 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
+$145K |
| 3 |
CPIG
Chicago Partners Investment Group
Chicago,
Illinois
|
+$75.4K |
| 4 |
VC
Voss Capital
Houston,
Texas
|
+$72.4K |
| 5 |
MWA
Meridian Wealth Advisors
Austin,
Texas
|
+$59.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO)
Austin,
Texas
|
-$221K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$104K |
| 3 |
BlackRock
New York
|
-$58K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$36.9K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$8.96K |
RNTX Hedge Fund Activity: Q1 2025 in Review
39 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Rein Therapeutics (RNTX) for Q1 2025, worth a combined $10.6M — down 19% from $13.1M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new RNTX positions and 2 closed out — a net gain of 8 holders — while 7 added to existing stakes and 6 trimmed.
The largest buyer was Vanguard Group, adding an estimated $612K. The largest seller was University of Texas/Texas AM Investment Management Co (UTIMCO), cutting an estimated $221K.
- 39 institutional investors held Rein Therapeutics (RNTX) as of Q1 2025, up from 31 in Q4 2024.
- Funds reported $10.6M of Rein Therapeutics stock for Q1 2025, down 19% quarter-over-quarter.
- 10 funds opened new Rein Therapeutics positions in Q1 2025 and 2 closed out, a net change of +8 holders.
- The largest Rein Therapeutics buyer in Q1 2025 was Vanguard Group, an estimated $612K added.
- The largest Rein Therapeutics seller in Q1 2025 was University of Texas/Texas AM Investment Management Co (UTIMCO), an estimated $221K sold.
Based on aggregated 13F filings for Q1 2025.